| DB ID | MyCo_2511 |
| Title | Optimization of cutoff values for (1→3)-β-d-glucan and galactomannan assays in cerebrospinal fluid for the diagnosis of non-cryptococcal fungal infections of the central nervous system |
| Year | 2025 |
| PMID | 40221133 |
| Fungal Diseases involved | Fungal infections of the central nervous system |
| Associated Medical Condition | None |
| Genus | Fusarium |
| Species | oxysporum |
| Organism | Fusarium oxysporum |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Cerebrospinal fluid (CSF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Multi-Location |
| Cohort | A total of 84 CSF samples were received for evaluation of fungal meningitis during the study period. |
| Cohort No. | 84 |
| Age Group | 38 ± 15.6 |
| P Value | None |
| Sensitivity | 0.96 |
| Specificity | 0.783 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA Kit- Platelia Aspergillus (Bio-Rad, Marnes-la-Coquette,Paris,France) |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay+FDA Approved -Platelia Aspergillus ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
